Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor

2 drugs the FDA files under Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor, and that we can price. Drugs in one class are not interchangeable — they share a mechanism, not a dose or a set of side effects — but the price gap between them is often large, and it is a reasonable thing to raise with a prescriber.